Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of “Buy” by Analysts

Fulcrum Therapeutics, Inc. (NASDAQ:FULCGet Rating) has been assigned a consensus recommendation of “Buy” from the nine brokerages that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $34.86.

A number of research firms have issued reports on FULC. Zacks Investment Research downgraded Fulcrum Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, March 8th. Bank of America raised Fulcrum Therapeutics from an “underperform” rating to a “neutral” rating in a research report on Thursday, March 3rd. Credit Suisse Group lifted their price target on Fulcrum Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Friday, March 25th. Morgan Stanley lifted their price target on Fulcrum Therapeutics from $25.00 to $26.00 and gave the company an “overweight” rating in a research report on Tuesday, April 12th. Finally, Oppenheimer began coverage on Fulcrum Therapeutics in a research report on Monday, March 7th. They issued an “outperform” rating and a $33.00 price target for the company.

In other Fulcrum Therapeutics news, Director Robert J. Gould sold 7,235 shares of Fulcrum Therapeutics stock in a transaction dated Monday, April 4th. The stock was sold at an average price of $24.02, for a total transaction of $173,784.70. Following the completion of the sale, the director now owns 506,630 shares of the company’s stock, valued at $12,169,252.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Robert J. Gould sold 34,464 shares of Fulcrum Therapeutics stock in a transaction dated Friday, April 1st. The stock was sold at an average price of $24.03, for a total value of $828,169.92. Following the sale, the director now directly owns 506,630 shares of the company’s stock, valued at approximately $12,174,318.90. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 47,330 shares of company stock valued at $1,137,211. 22.30% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Fulcrum Therapeutics during the fourth quarter worth about $47,000. Royal Bank of Canada lifted its stake in shares of Fulcrum Therapeutics by 113.4% in the 3rd quarter. Royal Bank of Canada now owns 3,240 shares of the company’s stock valued at $91,000 after acquiring an additional 1,722 shares during the last quarter. Denali Advisors LLC bought a new stake in shares of Fulcrum Therapeutics in the 4th quarter valued at about $69,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Fulcrum Therapeutics in the 4th quarter valued at about $103,000. Finally, Metropolitan Life Insurance Co NY bought a new stake in shares of Fulcrum Therapeutics in the 3rd quarter valued at about $204,000. 90.41% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:FULC opened at $10.98 on Friday. The business has a fifty day simple moving average of $15.77 and a two-hundred day simple moving average of $16.77. Fulcrum Therapeutics has a 1 year low of $6.85 and a 1 year high of $33.10. The company has a market capitalization of $446.19 million, a P/E ratio of -4.79 and a beta of 1.96.

Fulcrum Therapeutics (NASDAQ:FULCGet Rating) last released its earnings results on Thursday, March 3rd. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.07. Fulcrum Therapeutics had a negative return on equity of 47.50% and a negative net margin of 421.89%. The business had revenue of $5.06 million during the quarter, compared to the consensus estimate of $4.00 million. During the same period last year, the business posted ($0.64) earnings per share. Analysts forecast that Fulcrum Therapeutics will post -2.58 EPS for the current year.

About Fulcrum Therapeutics (Get Rating)

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Further Reading

Analyst Recommendations for Fulcrum Therapeutics (NASDAQ:FULC)

Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.